DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose ...

DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 ...

The healthcare industry presents a wealth of opportunities for investors to generate notable portfolio returns over decades.

Adults with type 2 diabetes who used a continuous glucose monitor and wore their sensor for more than 270 days in 1 year had ...

Abbott has launched an effort to replace some of its FreeStyle Libre 3 continuous glucose monitors—following reports of ...

Abbott has initiated a medical device correction for sensors used in certain FreeStyle Libre 3 continuous glucose monitoring (CGM) systems in the US after determining that some of them may be ...

MILWAUKEE, Nov. 24, 2025 /PRNewswire/ — Ademi & Fruchter LLP is investigating possible securities fraud claims against DexCom, Inc. (NASDAQ: DXCM). The investigation results from inaccurate statements ...

The problem applies to Abbott’s Libre 3 and Libre 3 Plus sensors. The company said it has received reports of 736 severe adverse events and seven deaths.

Touchstone Sands Capital Select Growth Fund Q3 review highlights AI-driven gains and challenges. Explore insights and ...

Explore Touchstone Sands Capital Select Growth Fund's Q3 2025 performance, AI strategy, and key holdings. Click here to ...

The figures show that preventing these complications alone could save more than $604 million in direct medical costs. CGMs ...

Abbott Laboratories said on Monday it has begun a correction in the United States for certain FreeStyle Libre 3 and FreeStyle ...